PBA
MRTX

Paradigm Biocapital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,543,116
Closed -$90.7M – 40
2023
Q4 		$90.7M Sell
1,543,116
-125,000
-7% -$7.03M 4.24% 11
2023
Q3 		$72.7M Buy
1,668,116
+224,354
+16% +$8.01M 4.93% 7
2023
Q2 		$52.2M Buy
1,443,762
+46,983
+3% +$1.94M 4.03% 11
2023
Q1 		$51.9M Buy
1,396,779
+128,809
+10% +$5.79M 4.92% 9
2022
Q4 		$57.5M Buy
1,267,970
+417,585
+49% +$27M 6.74% 3
2022
Q3 		$59.4M Buy
850,385
+190,417
+29% +$14.1M 7.92% 2
2022
Q2 		$44.3M Buy
659,968
+561,585
+571% +$35.7M 8.83% 3
2022
Q1 		$8.09M Sell
98,383
-161,732
-62% -$16.5M 2.14% 19
2021
Q4 		$38.2M Buy
+260,115
New +$40.4M 10.9% 1

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Paradigm Biocapital Advisors's MRTX Position: Q1 2024 in Review

Paradigm Biocapital Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 1,543,116 shares — an estimated $90.7M sold.

Paradigm Biocapital Advisors first reported a position in MRTX in Q4 2021 and held it in 9 quarters. The position peaked at $90.7M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Paradigm Biocapital Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 1,543,116 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $90.7M.
  • Paradigm Biocapital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Paradigm Biocapital Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $90.7M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2024, filed 15 May 2024.